Prevotella copri alleviates hyperglycemia and regulates gut microbiota and metabolic profiles in mice

作者：Caixin Yang, Ruiting Lan, Zhao Lijun, Ji Pu, Dalong Hu, Jing Yang, Huimin Zhou, Lichao Han, Lin Ye, Dong Jin, Jianguo Xu, Liyun Liu · 发表于：mSystems · 年份：2024 · DOI：10.1128/msystems.00532-24 · 被引用次数：28 · 研究领域：Gut microbiota and health、Probiotics and Fermented Foods、Diet and metabolism studies

ABSTRACT Prevotella copri is the dominant species of the Prevotella genus in the gut, which is genomically heterogeneous and difficult to isolate; hence, scarce research was carried out for this species. This study aimed to investigate the effect of P. copri on hyperglycemia. Thirty-nine strains were isolated from healthy individuals, and three strains (HF2123, HF1478, and HF2130) that had the highest glucose consumption were selected to evaluate the effects of P. copri supplementation on hyperglycemia. Microbiomics and non-target metabolomics were used to uncover the underlying mechanisms. Oral administration of P. copri in diabetic db/db mice increased the expression and secretion of glucagon-like peptide-1 (GLP-1), significantly improved hyperglycemia, insulin resistance, and lipid accumulation, and alleviated the pathological morphology in the pancreas, liver, and colon. P. copri changed the composition of the gut microbiota of diabetic db/db mice, which was characterized by increasing the ratio of Bacteroidetes to Firmicutes and increasing the relative abundance of genera Bacteroides , Akkermansia , and Faecalibacterium . After intervention with P. copri , fecal metabolic profiling showed that fumaric acid and homocysteine contents decreased, and glutamine contents increased. Furthermore, amino acid metabolism and cAMP/PKA signaling pathways were enriched. Our findings indicate that P. copri improved glucose metabolism abnormalities in diabetic db/db mice. Especially, on...